Pages that link to "Q73833112"
Jump to navigation
Jump to search
The following pages link to Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma (Q73833112):
Displaying 13 items.
- Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy (Q24792394) (← links)
- Metastasis to bone: causes, consequences and therapeutic opportunities (Q29614310) (← links)
- Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. (Q33705995) (← links)
- Human prostate cancer risk factors (Q34360616) (← links)
- Bone markers in the management of patients with skeletal metastases (Q35053972) (← links)
- Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis (Q35147059) (← links)
- Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622 (Q36090747) (← links)
- Markers of bone turnover for the management of patients with bone metastases from prostate cancer (Q36641310) (← links)
- Collagen crosslink excretion and staging of oral cancer (Q36646700) (← links)
- Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples (Q36671503) (← links)
- Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications (Q36846769) (← links)
- Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. (Q37696687) (← links)
- The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies (Q73035104) (← links)